WinstonWınston
Back
Stock

Ainos

AIMD
15
Biotechnology · Healthcare
Price
$1.52
-0.04 (-2.56%)
Market Cap
$11.2M
Exchange
NASDAQ Capital Market
Winston Score
15
Winston is worried
Weak fundamentals across most pillars.
Data as of Sep 4, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality
Weak
Growth
Weak
Cash Flow
Weak
Stability
Weak
Valuation
Data not available
Track this stock — start free trial

Share count rising — dilution

+182.8% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 1.5M (2021) → 4.3M (2025)

§Winston Score History

The full picture

Ainos is a small biotechnology company focused on developing AI-powered medical diagnostics and antiviral products. Its key products include a rapid COVID-19 saliva test and an air purification device designed to inactivate viruses. The company targets healthcare providers and general consumers, primarily in Taiwan and the United States.

Ainos generates revenue through product sales of its diagnostic devices and antiviral solutions, though the company is still in a very early stage with minimal revenue and significant operating losses. It is a micro-cap company with limited commercial traction so far. The main risk facing Ainos is whether it can successfully commercialize its products and raise enough capital to sustain operations, as its deeply negative margins reflect a business that has not yet achieved meaningful scale.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-96.7% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+37.4% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$8M/ year

↓ Declining (-8% vs prior year)

>1,000% of revenue

346.8x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

53.3%ownership

Insiders own a meaningful stake in the company

Cash Runway

~3 months

$1M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

Ainos has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
-780350.0%
Thin — -780350.0% gross margin
Profit after running costs
Operating Margin
-2894135.5%
Losing money on operations — -2894135.5%
Return on the money invested
ROCE
-80.5%
Weak — -80.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-87.7%
Shrinking sales (-87.7% YoY)
Profit growth
EPS YoY
N/A
—
Data not available
How steady the profit is
EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
—
Data not available
Spare cash per sale
FCF Margin
-33069.4%
Burning cash (-33069.4%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
4.21
Heavy debt load (4.21)
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
—
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial